SANN Stock Overview
A specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Santhera Pharmaceuticals Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 9.18 |
| 52 Week High | CHF 14.62 |
| 52 Week Low | CHF 7.14 |
| Beta | 0.13 |
| 11 Month Change | 11.00% |
| 3 Month Change | -3.37% |
| 1 Year Change | 11.95% |
| 33 Year Change | -59.56% |
| 5 Year Change | -93.84% |
| Change since IPO | -98.99% |
Recent News & Updates
Shareholder Returns
| SANN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 1.2% | -5.8% | -1.0% |
| 1Y | 12.0% | 79.9% | 2.8% |
Return vs Industry: SANN underperformed the Swiss Biotechs industry which returned 80.2% over the past year.
Return vs Market: SANN exceeded the Swiss Market which returned 5.3% over the past year.
Price Volatility
| SANN volatility | |
|---|---|
| SANN Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.1% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: SANN has not had significant price volatility in the past 3 months.
Volatility Over Time: SANN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 45 | Dario Eklund | www.santhera.com |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases.
Santhera Pharmaceuticals Holding AG Fundamentals Summary
| SANN fundamental statistics | |
|---|---|
| Market cap | CHF 84.59m |
| Earnings (TTM) | CHF 54.78m |
| Revenue (TTM) | CHF 103.41m |
1.5x
P/E Ratio0.8x
P/S RatioIs SANN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANN income statement (TTM) | |
|---|---|
| Revenue | CHF 103.41m |
| Cost of Revenue | CHF 3.24m |
| Gross Profit | CHF 100.18m |
| Other Expenses | CHF 45.40m |
| Earnings | CHF 54.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.94 |
| Gross Margin | 96.87% |
| Net Profit Margin | 52.97% |
| Debt/Equity Ratio | 34.9% |
How did SANN perform over the long term?
See historical performance and comparison